NetraMark, a wholly owned subsidiary of Nurosene, is providing next-generation AI solutions for pharmaceutical and biotechnology companies.



Increase efficiency, reduce costs and failure rate.

NetraAI has been proven to accelerate traditional research by 10 - 100x. NetraAI allows pharma companies to better understand the efficacy of their drugs and how to design better clinical trials in order to avoid expensive failures.

Drug resurrection

Reigniting failed clinical trials with improved intelligence and methodologies to brings drugs back to market. Our data suggests that partnering together we can show a 3 in 10 chance of success versus a 1 in 10000 chance.

Drug repurposing

For new indications as identified through databases of molecules, disease interaction, and our NetraAI technology.

New molecule invention

Using mathematical and machine intelligence technologies for determining molecular docking and binding affinities for new drug inventions through precision drug targets discovered by the NetraAI technology.

Meet the Team

We’re a team of mathematicians, scientists, doctors, and pharma experts.

Our technology orchestrates, organizes, and applies various machine learning methods to process complex data.

Black & green data lines
Black & green data lines